Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

This is a new option that oncologists should consider for frail patients who have soft tissue sarcoma.